SIRT3 expression improves prognosis in gastric cancer
As reported in the World Journal of Surgery, SIRT3 expression improves the prognosis in patients with gastric cancer (n=221). Specifically, the 5-year OS was 51.2% and 39.1% in patients who do and do not express SIRT3, respectively. The 5-year DFS was 49.6% and 38.0% in patients who do and do not express SIRT3, respectively. Patients who do not express SIRT3 are characterized by increased poor cellular differentiation, increased diffuse-type Lauren’s histology, and increases scirrhous-type stromal reactions, suggesting the SIRT3 functions as a tumor suppressor.
Increased MMP-9 expression associated with poor prognosis in CRC
As reported in the World Journal of Surgical Oncology, the expression of MMP-9 in colon cancer tissues was increased compared to distal normal mucosa (69.1% vs. 2.9%). Increased MMP-9 expression was associated with lymph node metastasis, Duke stage, and decreased survival.
Risk factors for intra-abdominal abscesses in Crohn’s disease
As reported in Digestion, uncontrolled CRP at week 14 of therapy with infliximab (OR=1.36) and early loss of response to infliximab (OR=5.36) are independent risk factors for intra-abdominal abscesses in patients with Crohns disease.